Carisma Therapeutics

Carisma Therapeutics

Carisma Therapeutics was founded in 2016, emerging from research by Dr. Saar Gill, Dr. Michael Klichinsky, and Dr. Carl June at the University of Pennsylvania's Perelman School of Medicine. The company develops off-the-shelf, engineered macrophage cell therapies for solid tumors, a segment where CAR-T cells have limited efficacy due to poor tumor infiltration and hostile microenvironments. Carisma's platform aims to convert macrophages from pro-tumor (M2) to anti-tumor (M1) phenotypes while targeting specific antigens. The company raised $53 million in Series A financing in 2018, led by AbbVie Ventures and Grazia Equity, with participation from Sanofi Ventures and others. In November 2020, Carisma completed a $59 million Series B round co-led by F-Prime Capital and Symbiosis Holdings. Carisma went public via SPAC merger with GX Acquisition Corp. II in April 2023, listing shares on the Nasdaq under the ticker 'CARM'. The transaction valued the company at approximately $286 million. As of its 2023 annual report, Carisma reported over $150 million in cash and cash equivalents. Carisma’s primary focus remains CT-0508, which entered Phase 1 clinical trials in 2021. The trial investigates safety and tolerability in patients with HER2-overexpressing solid tumors. The company also has preclinical programs targeting mesothelin and other solid-tumor antigens. Carisma operates from Philadelphia, Pennsylvania, where the Penn spin-out maintains research facilities. Unlike many cell-therapy firms that exclusively pursue CAR-T for hematologic cancers, Carisma targets solid tumors by engineering macrophages -- a structural differentiator in the cell-therapy landscape. This approach leverages the innate ability of macrophages to infiltrate dense stromal tissue, potentially overcoming a key barrier in solid-tumor treatment. The company's reliance on SPAC financing and a single clinical-stage candidate places it in a high-risk, high-reward segment of the biotech sector.